CTN Bulletin logo
August 2, 2018

Save the Date: 2019 CTN Steering Committee Meeting



CTN Steering Committee

Registration information will be available in early 2019. (Watch the CTN Bulletin for updates!)

NIDA's Chief of Chemistry and Pharmacology to Receive First Hall of Fame Award at Conference on Chemistry & Pharmacology of Drug Abuse

Rao RapakaDr. Rao S. Rapaka, Chief of the Chemistry and Pharmacology Branch in the Division of Neuroscience and Behavior at the National Institute on Drug Abuse, will receive the first Hall of Fame award from the Conference on Chemistry and Pharmacology of Drug Abuse (SCPDA). He will receive this award for his outstanding and visionary contributions and service to the field of drug abuse research and medication discovery. The SCPDA Hall of Fame award was established in 2016 to recognize senior investigators with long-standing records of achievements who have made exceptional contributions to chemistry and pharmacology of drug abuse through research, teaching and/or service. Dr. Rapaka will receive this award at the CPDA Annual Meeting on August 2-3 at Northeastern University in Boston, MA.

CTN Trial Progress

GraphStudy results for Open Studies as of the July 25 trial Progress Report.

CTN-0064 - Linkage to HCV Care.
Enrolled 113

CTN-0067 - CHOICES Scale-Up. Enrolled 32

CTN-0068 - ADAPT-2 for Methamphetamine Use Disorder. Enrolled 225

CTN-0069 - OUD in the Emergency Department. Enrolled 349

CTN-0073 - Detecting Cocaine Use Using Smart watches. Enrolled 19

CTN-0075 - Physician-Pharmacist Collaboration - OUD
Enrolled 39

Total Enrolled in all Studies: 24,883

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Submit Your Posters & Presentations from CPDD to the CTN Dissemination Library!

CPDD logoDid you present about CTN-related research at this year’s CPDD conference? If so, we would love to get a copy of your slides! Please send them to us at info@ctndisseminationlibrary.organd we can add them to the CTN Dissemination Library!

We'll be keeping a running list of all the CPDD 2018 items we add to the Library on our What's New blog.

Right now we have 8 posters, including one about an ancillary investigation of data from CTN-0062-Ot that seeks to integrate screening and clinical interventions for unhealthy alcohol and drug use into rural primary care clinics, and 7 about CTN-0051 (X:BOT), including a poster presenting their primary outcomes, which were also published in The Lancet last year.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New from the Northeast Node

OV NodeNortheast Node awarded CTN-0083: Using Social Media to Deliver HIV Self-Testing Kits and Link to Online PrEP Services

The Northeast Node is excited to announce the award of CTN-0083: Using Social Media to Deliver HIV Self-Testing Kits and Link to Online PrEP Services, led by Dr. Jeffrey Klausner of UCLA in collaboration with Dr. Sean Young of UCLA, and Dr. Lisa Marsch of the Northeast Node.

Despite accounting for only 6% of the US population, men who have sex with men (MSM) account for 53% of all people living with HIV. The targeted promotion of HIV self-testing and simplified access to test kits and PrEP (pre-exposure prophylaxis) medication is a promising approach to HIV prevention among this high-risk population.

Online services are increasingly becoming a platform for efficiently delivering public health campaigns and targeting those in need who may be missed by other conventional forms of prevention outreach (e.g. physicians).

In this study, MSM between 18-30 years old will receive culturally-relevant advertisements targeting minorities. Compared to all other age groups, regardless of sexual preferences, those under 30 are the age group that are the most likely to be active and engaged daily social media users.

The proposed study aims are to:

  • Adapt existing social media-based HIV self-testing and PrEP advertising materials for digital distribution on social media and informational sites

  • Compare the relative effectiveness of using popular social media sites like Facebook, Grindr, and Hornet versus commonly used information sites like Google (where individuals are searching for relevant informational content) to promote HIV home self-testing and PrEP uptake.

We will also determine how substance use modifies key outcomes such as HIV testing and PrEP uptake.

Two hundred MSM will be recruited to participate in this study via web-based enrollment, allowing for a geographically diverse study population. A study website and social media ads will be developed by collaborators from YTH.org, a health and technology-based design corporation.

This study has important public health implications. HIV infection results in substantial personal, societal, and financial costs at a global scale. This preventable public health issue can be addressed by harnessing the infrastructure of social media services and using those platforms to deliver cost-effective prevention interventions such as HIV testing and PrEP to large numbers of individuals.

The Northeast Node is greatly looking forward to collaborating with the team at UCLA, who has pioneered work in the field, and to participate in this novel utilization of social media to increase HIV testing and PrEP uptake.

New from the Library

Journal articles

Prevalence of behavioral health conditions across frequency of cannabis use among adult primary care patients in Washington State. Lapham GT, et al. Journal of General Internal Medicine 2018 (in press).
Asking about the frequency of cannabis use as part of routine behavioral health screening in primary care in a state with legalized use better identifies patients at increased risk for substance use and mental health conditions. [Read more here. . .]

Biological Correlates of Self-Reported New and Continued Abstinence in Cannabis Cessation Treatment Clinical Trials. Baker NL, et al. Drug and Alcohol Dependence 2018;178:270-277.
Using combinations of biological measurements (urinalysis, e.g.) and self-reported abstinence, confirmation of study-related abstinence may be verifiable earlier and with greater accuracy than relying on a single measurement. [Read more here. . .]

Protocol Information Pages

Emergency Medicine Opioid Data Infrastructure: Key Venus to Address Opioid Morbidity and Mortality (Project CODE PRO - Capturing Opioid Use Disorder Electronically and Patient-Reported Outcomes). Lead Node: New England Consortium.

Implementation Survey of PrEP and Opioid Use Related Services in STI Clinics and MSM-Centered Community Based Organizations (CBOs). Lead Nodes: Pacific Northwest and Greater New York.

Using Social Media to Deliver HIV Self-Testing Kits and Link to Online PrEP Services. Lead Node: Northeast.


Where is MAT Available in the U.S. and Is It Available Where Needed? A Geographic Review. July 30, 2018. Presented by Martin Y. Iguchi.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New from the ATTC

ATTC Messenger: July 2018
Featured Article: Mountain Plains ATTC Serves Six States in Region 8 - Susan Mickelson, Mountain Plains ATTC

From the ATTC|NIATx Service Improvement Blog

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

CTN Investigator's Toolbox Updates

The Investigator Toolbox on the CTN Report website has recently been updated to add a new document entitled “List of Required Regulatory Documents for CTN Trials.” (Note: Access to the Report website and these tools are restricted; if you would like to request access, contact the NIDA DSC help desk at nidadsc2help@emmes.com.)

This document, located under the “Pre-Implementation / Regulatory” section of the Investigator Toolbox, provides an overview of the regulatory documents that are typically required in CTN trials and the process through which these documents are collected.

The Investigator’s Agreement Guidance Document and the Form FDA 1572 Guidance Document have also recently been updated. Check them out under the “Pre-Implementation / Regulatory” section of the Investigator Toolbox.

If you have any questions about the Investigator Toolbox or suggestions for new documents to add to the Toolbox, please contact Dee Blumberg (dblumberg@emmes.com) and Julia Collins (jcollins@emmes.com) at the Clinical Coordinating Center.



Published by the CTN Dissemination Library of the Pacific Northwest Node
Alcohol & Drug Abuse Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol & Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe

Copyright (C) 2016 Alcohol and Drug Abuse Institute. All rights reserved.